Related references
Note: Only part of the references are listed.Islet Amyloid Polypeptide: Structure, Function, and Pathophysiology
Rehana Akter et al.
JOURNAL OF DIABETES RESEARCH (2016)
Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1 via the nucleotide-binding domain and leucine-rich repeat containing family pyrin 3(NLRP3)-inflammasome activation: a possible implication for therapeutic decision in these patients
P. Ruscitti et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2015)
Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome
Isabelle Kone-Paut et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2015)
The Role of IL-1β in the Bone Loss during Rheumatic Diseases
Piero Ruscitti et al.
MEDIATORS OF INFLAMMATION (2015)
Macrophages are essential for CTGF-mediated adult β-cell proliferation after injury
Kimberly G. Riley et al.
MOLECULAR METABOLISM (2015)
FRI0219 Disease severity, no steroid use and type ii diabetes predict response to anakinra (kineret®) in patients with rheumatoid arthritis
B. Missler-Karger et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance
P. C. M. van Poppel et al.
DIABETES OBESITY & METABOLISM (2014)
Anakinra for cryopyrin-associated periodic syndrome
Isabelle Kone-Paut et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2014)
Caspases and inflammasomes in metabolic inflammation
Alexander M. Skeldon et al.
IMMUNOLOGY AND CELL BIOLOGY (2014)
Targeting inflammation in the treatment of type 2 diabetes: time to start
Marc Y. Donath
NATURE REVIEWS DRUG DISCOVERY (2014)
Understanding and Modulating the Toll Like Receptors (TLRs) and NOD Like Receptors (NLRs) Cross Talk in Type 2 Diabetes
Bhumika Prajapati et al.
CURRENT DIABETES REVIEWS (2014)
Upregulated NLRP3 Inflammasome Activation in Patients With Type 2 Diabetes
Hye-Mi Lee et al.
DIABETES (2013)
Macrophages and islet inflammation in type 2 diabetes
K. Eguchi et al.
DIABETES OBESITY & METABOLISM (2013)
Role of pancreatic β-cell death and inflammation in diabetes
W. Quan et al.
DIABETES OBESITY & METABOLISM (2013)
Macrophages control innate inflammation
S. Akira et al.
DIABETES OBESITY & METABOLISM (2013)
The Interleukin-1 Family: Back to the Future
Cecilia Garlanda et al.
IMMUNITY (2013)
Prevalence and out-patient medical costs of comorbid conditions in patients with rheumatoid arthritis
Manathip Osiri et al.
JOINT BONE SPINE (2013)
Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials
Antoinette Moran et al.
LANCET (2013)
Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis
Katherine P. Liao et al.
RHEUMATOLOGY (2013)
Overview of the interleukin-1 family of ligands and receptors
Charles A. Dinarello
SEMINARS IN IMMUNOLOGY (2013)
MHC class II polymorphisms, autoreactive T-cells, and autoimmunity
Sue Tsai et al.
FRONTIERS IN IMMUNOLOGY (2013)
Saturated Fatty Acid and TLR Signaling Link β Cell Dysfunction and Islet Inflammation
Kosei Eguchi et al.
CELL METABOLISM (2012)
Effects of Interleukin-1β Inhibition With Canakinumab on Hemoglobin A1c, Lipids, C-Reactive Protein, Interleukin-6, and Fibrinogen A Phase IIb Randomized, Placebo-Controlled Trial
Paul M. Ridker et al.
CIRCULATION (2012)
Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes
Claudia Cavelti-Weder et al.
DIABETES CARE (2012)
Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial
A. Rissanen et al.
DIABETES OBESITY & METABOLISM (2012)
Managing Macrophages in Rheumatoid Arthritis by Reform or Removal
Jun Li et al.
CURRENT RHEUMATOLOGY REPORTS (2012)
Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study
Rieke Alten et al.
BMC MUSCULOSKELETAL DISORDERS (2011)
Treatment with Anakinra Improves Disposition Index But Not Insulin Sensitivity in Nondiabetic Subjects with the Metabolic Syndrome: A Randomized, Double-Blind, Placebo-Controlled Study
Edwin J. P. van Asseldonk et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells
Helga Ellingsgaard et al.
NATURE MEDICINE (2011)
Type 2 diabetes as an inflammatory disease
Marc Y. Donath et al.
NATURE REVIEWS IMMUNOLOGY (2011)
Immunotherapy of Rheumatoid Arthritis Targeting Inflammatory Cytokines and Autoreactive T Cells
Guangjie Chen
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS (2010)
Kinetic Approach to Pathway Attenuation Using XOMA 052, a Regulatory Therapeutic Antibody That Modulates Interleukin-1β Activity
Marina K. Roell et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Acute cytokine-mediated downregulation of the zinc transporter ZnT8 alters pancreatic β-cell function
Malek El Muayed et al.
JOURNAL OF ENDOCRINOLOGY (2010)
Thioredoxin-interacting protein links oxidative stress to inflammasome activation
Rongbin Zhou et al.
NATURE IMMUNOLOGY (2010)
Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1 beta in type 2 diabetes
Seth L. Masters et al.
NATURE IMMUNOLOGY (2010)
The NLRP3 Inflammasome: A Sensor for Metabolic Danger?
Kate Schroder et al.
SCIENCE (2010)
Role of IL-1β in type 2 diabetes
Charles A. Dinarello et al.
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY (2010)
The Inflammasomes: Guardians of the Body
Fablo Martinon et al.
ANNUAL REVIEW OF IMMUNOLOGY (2009)
Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes
Claus M. Larsen et al.
DIABETES CARE (2009)
Free Fatty Acids Induce a Proinflammatory Response in Islets via the Abundantly Expressed Interleukin-1 Receptor I
Marianne Boeni-Schnetzler et al.
ENDOCRINOLOGY (2009)
Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
Helen J. Lachmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat
J. A. Ehses et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
The antiinflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia
Nadine S. Sauter et al.
ENDOCRINOLOGY (2008)
Increased interleukin (IL)-1β messenger ribonucleic acid expression in β-cells of individuals with type 2 diabetes and regulation of IL-1β in human islets by glucose and autostimulation
Marianne Boni-Schnetzler et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis
Rieke Alten et al.
ARTHRITIS RESEARCH & THERAPY (2008)
Exploring the full spectrum of macrophage activation
David M. Mosser et al.
NATURE REVIEWS IMMUNOLOGY (2008)
T cell dependence of chronic destructive murine arthritis induced by repeated local activation of toll-like receptor-driven pathways
Leo A. B. Joosten et al.
ARTHRITIS AND RHEUMATISM (2008)
High glucose induces IL-1β expression in human monocytes:: mechanistic insights
Mohan R. Dasu et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2007)
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Claus M. Larsen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
The Fas pathway is involved in pancreatic β cell secretory function
Desiree M. Schumann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Low concentration of interleukin-1β induces FLICE-inhibitory protein-mediated β-cell proliferation in human pancreatic islets (Publication with Expression of Concern. See vol. 65, pg. 2462, 2016) (Publication with Expression of Concern. See vol. 65, pg. 2462, 2016) (Publication with Expression of Concern. See vol. 67, pg. 2479, 2018)
Kathrin Maedler et al.
DIABETES (2006)
A transient microenvironment loaded mainly with macrophages in the early developing human pancreas
L Banaei-Bouchareb et al.
JOURNAL OF ENDOCRINOLOGY (2006)
Hypoxia regulates macrophage functions in inflammation
C Murdoch et al.
JOURNAL OF IMMUNOLOGY (2005)
Is there a role for locally produced interleukin-1 in the deleterious effects of high glucose or the type 2 diabetes milieu to human pancreatic islets?
N Welsh et al.
DIABETES (2005)
The chemokine system in diverse forms of macrophage activation and polarization
A Mantovani et al.
TRENDS IN IMMUNOLOGY (2004)
Leptin modulates β cell expression of IL-1 receptor antagonist and release of IL-lβ in human islets
K Maedler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Hypoxia-induced gene expression in human macrophages - Implications for ischemic tissues and hypoxia-regulated gene therapy
B Burke et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
Bone destruction in arthritis
EM Gravallese
ANNALS OF THE RHEUMATIC DISEASES (2002)
Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
K Maedler et al.
JOURNAL OF CLINICAL INVESTIGATION (2002)
Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage
SB Abramson et al.
RHEUMATOLOGY (2002)
Cytokine imbalance in the pathogenesis of rheumatoid arthritis: The role of interleukin-1 receptor antagonist
WP Arend
SEMINARS IN ARTHRITIS AND RHEUMATISM (2001)
Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice
R Horai et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
